KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2)

Furthermore, TBG appears to induce structural neuroplasticity without the widespread induction of immediate early genes (IEGs) seen with classical hallucinogens, suggesting a decoupling of therapeutic rewiring from the subjective psychedelic experience. This review synthesizes current preclinical evidence to discuss TBG as a promising chemical scaffold for next-generation neurotherapeutics targeting the intersection of psychiatry and neurology.

These results suggest that amodiaquine derivatives have anti-COAD actions due to their disruption of important immune-regulatory and apoptotic pathways. These findings computationally prioritize amodiaquine and desethylamodiaquine as candidate multi-target interactors in colon adenocarcinoma, warranting further experimental investigation rather than implying established therapeutic efficacy.

P2/3, N=64, Recruiting, Thryv Therapeutics, Inc. | Not yet recruiting --> Recruiting

These findings provide insights into the potential oncologic implications of antipsychotic drug use and may inform clinical management.

The integrated machine learning and network toxicology approach developed in this study is reliable. Pesticides predicted to have potential cardiotoxicity require prioritized prevention during use.

P1/2, N=42, Terminated, Thryv Therapeutics, Inc. | N=28 --> 42 | Active, not recruiting --> Terminated; Advancing an alternative SGK1 inhibitor.

P=N/A, N=600, Recruiting, Nantes University Hospital | Trial completion date: Mar 2025 --> Mar 2026

P2, N=16, Completed, Istituto Auxologico Italiano | Recruiting --> Completed

Such complexes showed significant conformational rearrangements, accompanied by a sharp decrease in the hydrogen bonds quantity, a drop in the binding free energy, and local melting of the DNA duplex. Moreover, the latter applied not only to sites of direct incompatibility, but also to parts where HASDI-G2 fully corresponded to the sequence of intercalation.

Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia; however, its long-term use can lead to cardiotoxicity, particularly in cases of acquired long QT syndrome (acLQTS), which may result in torsade de pointes (TdP)...Tanshinone IIA and fexofenadine restored the hERG protein levels potentially by decreasing MALAT1 expression and counteracting ATO's effects on the MALAT1/calpain-1 pathway. Collectively, our research uncovers a previously unreported regulatory mechanism underlying ATO-induced acLQTS. Moreover, it identifies potential molecular targets and intervention strategies for acLQTS therapy.

P1/2, N=28, Active, not recruiting, Thryv Therapeutics, Inc. | Recruiting --> Active, not recruiting

hERG1 and nNav1.5 channels along with β1 integrins and the NHE1 antiporter are co-expressed in BCa both at gene and protein levels, assembling into a macromolecular complex. The NHE1/hERG1/β1/nNaV1.5 complex can be considered a novel biomarker and potential target for therapy for BCa patients.